2014 Q2 Form 10-Q Financial Statement

#000114420414046802 Filed on August 04, 2014

View on sec.gov

Income Statement

Concept 2014 Q2 2013 Q2
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $960.0K $1.070M
YoY Change -10.28% 18.89%
% of Gross Profit
Research & Development $1.381M $1.649M
YoY Change -16.26% 25.42%
% of Gross Profit
Depreciation & Amortization $90.00K $110.0K
YoY Change -18.18% -15.38%
% of Gross Profit
Operating Expenses $1.381M $1.649M
YoY Change -16.26% 25.42%
Operating Profit -$2.546M -$2.723M
YoY Change -6.5% 23.11%
Interest Expense -$114.0K -$2.216K
YoY Change 5043.05% 6.9%
% of Operating Profit
Other Income/Expense, Net $459.8K $658.1K
YoY Change -30.14% -3508.74%
Pretax Income -$2.090M -$2.060M
YoY Change 1.46% -7.62%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$2.086M -$2.064M
YoY Change 1.04% -7.46%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$69.67M -$68.67M
COMMON SHARES
Basic Shares Outstanding 57.40M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2014 Q2 2013 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.630M $5.830M
YoY Change -72.04% -18.46%
Cash & Equivalents $1.626M $5.828M
Short-Term Investments
Other Short-Term Assets $390.0K $210.0K
YoY Change 85.71% 5.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $2.020M $6.031M
YoY Change -66.5% -17.84%
LONG-TERM ASSETS
Property, Plant & Equipment $2.190M $2.513M
YoY Change -12.87% -10.55%
Goodwill $1.675M
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $10.00K $27.22K
YoY Change -63.27% -9.26%
Total Long-Term Assets $3.870M $6.094M
YoY Change -36.5% 35.13%
TOTAL ASSETS
Total Short-Term Assets $2.020M $6.031M
Total Long-Term Assets $3.870M $6.094M
Total Assets $5.890M $12.13M
YoY Change -51.42% 2.32%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.070M $1.020M
YoY Change 4.9% 67.21%
Accrued Expenses $130.0K
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $40.00K $0.00
YoY Change
Total Short-Term Liabilities $4.078M $6.091M
YoY Change -33.05% 851.7%
LONG-TERM LIABILITIES
Long-Term Debt $4.210M $450.0K
YoY Change 835.56% 0.0%
Other Long-Term Liabilities $150.0K $140.0K
YoY Change 7.14% 7.69%
Total Long-Term Liabilities $4.351M $590.2K
YoY Change 637.25% 1.76%
TOTAL LIABILITIES
Total Short-Term Liabilities $4.078M $6.091M
Total Long-Term Liabilities $4.351M $590.2K
Total Liabilities $8.429M $6.681M
YoY Change 26.16% 447.63%
SHAREHOLDERS EQUITY
Retained Earnings -$56.09M
YoY Change
Common Stock $29.00 $574.00
YoY Change -94.95%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$2.541M $5.444M
YoY Change
Total Liabilities & Shareholders Equity $5.889M $12.13M
YoY Change -51.43% 2.32%

Cashflow Statement

Concept 2014 Q2 2013 Q2
OPERATING ACTIVITIES
Net Income -$2.086M -$2.064M
YoY Change 1.04% -7.46%
Depreciation, Depletion And Amortization $90.00K $110.0K
YoY Change -18.18% -15.38%
Cash From Operating Activities -$2.010M -$2.030M
YoY Change -0.99% 35.33%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00
YoY Change
Cash From Investing Activities $0.00 $0.00
YoY Change -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -170.0K -10.00K
YoY Change 1600.0% -100.21%
NET CHANGE
Cash From Operating Activities -2.010M -2.030M
Cash From Investing Activities 0.000 0.000
Cash From Financing Activities -170.0K -10.00K
Net Change In Cash -2.180M -2.040M
YoY Change 6.86% -160.71%
FREE CASH FLOW
Cash From Operating Activities -$2.010M -$2.030M
Capital Expenditures $0.00 $0.00
Free Cash Flow -$2.010M -$2.030M
YoY Change -0.99% 36.24%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2013Q4 us-gaap Goodwill
Goodwill
1675462 USD
CY2013Q4 us-gaap Assets Current
AssetsCurrent
2768071 USD
CY2013Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
294687 USD
CY2013Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2360534 USD
CY2013Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
11872 USD
CY2013Q4 us-gaap Assets
Assets
6815939 USD
CY2014Q2 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2014Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-56088817 USD
CY2014Q2 us-gaap Stockholders Equity
StockholdersEquity
-2540618 USD
CY2014Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
5888562 USD
CY2014Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
53548170 USD
CY2013Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
143234 USD
CY2013Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
450000 USD
CY2014Q2 us-gaap Common Stock Value
CommonStockValue
29 USD
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
634658 shares
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2418384 USD
CY2013Q4 us-gaap Restricted Cash And Investments Current
RestrictedCashAndInvestmentsCurrent
55000 USD
CY2014Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1195418 USD
CY2014Q2 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
2840557 USD
CY2014Q2 us-gaap Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
431 USD
CY2014Q2 us-gaap Liabilities Current
LiabilitiesCurrent
4077736 USD
CY2014Q2 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
3796781 USD
CY2013Q4 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
0 USD
CY2014Q2 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
4351444 USD
CY2014Q2 us-gaap Liabilities
Liabilities
8429180 USD
CY2014Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2014Q2 us-gaap Certificates Of Deposit At Carrying Value
CertificatesOfDepositAtCarryingValue
55000 USD
CY2013Q4 us-gaap Certificates Of Deposit At Carrying Value
CertificatesOfDepositAtCarryingValue
55000 USD
CY2014Q2 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
551365 shares
CY2013Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
826365 shares
CY2014Q2 us-gaap Convertible Debt Fair Value Disclosures
ConvertibleDebtFairValueDisclosures
2556000 USD
CY2013 us-gaap Fair Value Assumptions Risk Free Interest Rate
FairValueAssumptionsRiskFreeInterestRate
0.0092 pure
us-gaap Fair Value Assumptions Risk Free Interest Rate
FairValueAssumptionsRiskFreeInterestRate
0.0176 pure
CY2013 us-gaap Fair Value Assumptions Expected Volatility Rate
FairValueAssumptionsExpectedVolatilityRate
1.09 pure
us-gaap Fair Value Assumptions Expected Volatility Rate
FairValueAssumptionsExpectedVolatilityRate
1.08 pure
CY2013 us-gaap Fair Value Assumptions Expected Term
FairValueAssumptionsExpectedTerm
P6Y
us-gaap Fair Value Assumptions Expected Term
FairValueAssumptionsExpectedTerm
P6Y
CY2014Q1 us-gaap Convertible Debt
ConvertibleDebt
4000000 USD
CY2014Q1 clrb Convertible Debentures And Warrants To Purchase Common Stock
ConvertibleDebenturesAndWarrantsToPurchaseCommonStock
400000 shares
CY2014Q1 clrb Payment For Convertible Debentures
PaymentForConvertibleDebentures
4000000 USD
CY2014Q1 clrb Securities Purchase Agreement Initiation Date
SecuritiesPurchaseAgreementInitiationDate
2014-02-05
CY2014Q1 us-gaap Debt Instrument Maturity Date
DebtInstrumentMaturityDate
2016-02-06
CY2014Q1 us-gaap Debt Instrument Convertible Conversion Price1
DebtInstrumentConvertibleConversionPrice1
10.00
CY2014Q1 us-gaap Debt Conversion Converted Instrument Shares Issued1
DebtConversionConvertedInstrumentSharesIssued1
400000 shares
CY2014Q1 us-gaap Debt Instrument Interest Rate Stated Percentage
DebtInstrumentInterestRateStatedPercentage
0.08 pure
CY2014Q1 clrb Gross Proceeds From Sale Of Securities
GrossProceedsFromSaleOfSecurities
2000000 USD
CY2014Q1 us-gaap Debt Instrument Interest Rate Effective Percentage
DebtInstrumentInterestRateEffectivePercentage
0.12 pure
CY2014Q1 clrb Payment On Default On Borrowings
PaymentOnDefaultOnBorrowings
100000 USD
CY2014Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
20.00
CY2014Q1 clrb Warrants Expiration Date
WarrantsExpirationDate
2019-02-06
CY2014Q1 clrb Default Value Of Borrowings
DefaultValueOfBorrowings
150000 USD
CY2014Q1 clrb Debt Conversion Converted Instrument Value Warrants Issued
DebtConversionConvertedInstrumentValueWarrantsIssued
254000 USD
us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
3746000 USD
CY2014Q2 us-gaap Deposit Liabilities Accrued Interest
DepositLiabilitiesAccruedInterest
128000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3239450 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3096105 USD
CY2013Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1648838 USD
CY2014Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1380798 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2195452 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2046921 USD
CY2013Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1073749 USD
CY2014Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
959885 USD
us-gaap Restructuring Costs
RestructuringCosts
0 USD
us-gaap Restructuring Costs
RestructuringCosts
221815 USD
CY2013Q2 us-gaap Restructuring Costs
RestructuringCosts
0 USD
CY2014Q2 us-gaap Restructuring Costs
RestructuringCosts
204934 USD
us-gaap Costs And Expenses
CostsAndExpenses
5434902 USD
us-gaap Costs And Expenses
CostsAndExpenses
5364841 USD
CY2013Q2 us-gaap Costs And Expenses
CostsAndExpenses
2722587 USD
CY2014Q2 us-gaap Costs And Expenses
CostsAndExpenses
2545617 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-5434902 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-5364841 USD
CY2013Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-2722587 USD
CY2014Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-2545617 USD
us-gaap Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net
DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
666384 USD
us-gaap Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net
DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
518806 USD
CY2013Q2 us-gaap Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net
DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
660341 USD
CY2014Q2 us-gaap Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net
DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
573751 USD
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-744957 USD
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
0 USD
CY2013Q2 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
0 USD
CY2014Q2 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
0 USD
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-4866 USD
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-183214 USD
CY2013Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-2216 USD
CY2014Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-113970 USD
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.03
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.75
CY2013Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.72
CY2014Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.73
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
2717966 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
2869739 shares
CY2013Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
2869739 shares
CY2014Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
2869739 shares
CY2014Q2 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
1964085 shares
us-gaap Share Based Compensation
ShareBasedCompensation
803791 USD
us-gaap Share Based Compensation
ShareBasedCompensation
536216 USD
CY2013Q2 us-gaap Share Based Compensation
ShareBasedCompensation
377893 USD
CY2014Q2 us-gaap Share Based Compensation
ShareBasedCompensation
273690 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.09 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.08 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0092 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0176 pure
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
14.80
CY2014Q2 clrb Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Options Unvested Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedOutstandingNumber
354911 shares
CY2014Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
264752 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
6.20
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
20000 shares
clrb Share Based Compensation Arrangement By Share Based Payment Award Options Cancelled In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod
20521 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
14474 shares
CY2014Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
619663 shares
CY2014Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
264752 shares
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
18.20
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
7.40
clrb Share Based Compensation Arrangements By Share Based Payment Award Options Cancelled In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice
23.17
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
15.00
CY2014Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
17.80
CY2014Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
29.00
CY2014Q2 clrb Share Based Compensation Arrangement By Share Based Payment Award Options Non Vested Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedExercisableWeightedAverageExercisePrice
9.20
CY2014Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
29.00
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P4Y14D
clrb Share Based Compensation Arrangement By Share Based Payment Award Options Unvested Outstanding Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingWeightedAverageRemainingContractualTerm
P9Y3M4D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P4Y14D
CY2014Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
0 USD
CY2014Q2 clrb Share Based Compensation Arrangement By Share Based Payment Award Options Unvested Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingAggregateIntrinsicValue
0 USD
CY2014Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
0 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
81805 shares
clrb Employee Service Share Based Compensation Nonvested Total Compensation In Current Year
EmployeeServiceShareBasedCompensationNonvestedTotalCompensationInCurrentYear
1096000 USD
clrb Employee Service Share Based Compensation Nonvested Total Compensation In Year Two
EmployeeServiceShareBasedCompensationNonvestedTotalCompensationInYearTwo
570000 USD
clrb Employee Service Share Based Compensation Nonvested Total Compensation In Year Three
EmployeeServiceShareBasedCompensationNonvestedTotalCompensationInYearThree
203000 USD
CY2014Q2 clrb Weighted Average Grant Date Fair Value Of Vested Options Outstanding
WeightedAverageGrantDateFairValueOfVestedOptionsOutstanding
16.66
CY2014Q2 clrb Weighted Average Grant Date Fair Value Of Unvested Options Outstanding
WeightedAverageGrantDateFairValueOfUnvestedOptionsOutstanding
5.98
CY2014Q2 clrb Share Based Compensation Arrangement By Sharebased Payment Award Options Unvested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedAndExpectedToVestOutstandingNumber
273106 shares
clrb Estimated Stock Based Compensation Expense Up On Vesting Of Options
EstimatedStockBasedCompensationExpenseUpOnVestingOfOptions
418000 USD
CY2014Q1 clrb Antidilution Option Reduced By Expiration Of Warrants
AntidilutionOptionReducedByExpirationOfWarrants
14474 shares
CY2014Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
10.00
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
219968 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
188369 USD
clrb Noncash Interest Expense Related To Discount On Convertible Debt
NoncashInterestExpenseRelatedToDiscountOnConvertibleDebt
0 USD
clrb Noncash Interest Expense Related To Discount On Convertible Debt
NoncashInterestExpenseRelatedToDiscountOnConvertibleDebt
50805 USD
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-2268 USD
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-3922597 USD
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-4602340 USD
us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
-121768 USD
us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
0 USD
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
28791 USD
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-15191 USD
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
0 USD
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
4000000 USD
us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
1178 USD
us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
1263 USD
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
70539 USD
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-172407 USD
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
5044514 USD
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
3825172 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
1150708 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-792359 USD
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4677545 USD
clrb Debt Conversion Converted Instrument Value Warrants Issued
DebtConversionConvertedInstrumentValueWarrantsIssued
254024 USD
clrb Payment Of Lump Sum Amount Related To Employment Agreement
PaymentOfLumpSumAmountRelatedToEmploymentAgreement
160000 USD
clrb Payment Towards Clinical Trial Agreements
PaymentTowardsClinicalTrialAgreements
264000 USD
CY2013Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5828253 USD
clrb Fair Value Of Warrants Classified As Derivative Liability
FairValueOfWarrantsClassifiedAsDerivativeLiability
5720000 USD
clrb Fair Value Of Warrants Classified As Derivative Liability
FairValueOfWarrantsClassifiedAsDerivativeLiability
0 USD
clrb Debt Conversion Converted Instrument Value Warrants Issued
DebtConversionConvertedInstrumentValueWarrantsIssued
0 USD
CY2014Q2 us-gaap Notes Payable Current
NotesPayableCurrent
41330 USD
CY2013Q4 us-gaap Notes Payable Current
NotesPayableCurrent
0 USD
us-gaap Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
-4391 USD
us-gaap Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
-2622 USD
clrb Reverse Stock Split Fractional Shares
ReverseStockSplitFractionalShares
0 USD
clrb Reverse Stock Split Fractional Shares
ReverseStockSplitFractionalShares
1158 USD
us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
At the annual meeting of stockholders held on May 22, 2014, the Company’s stockholders approved an amendment to the certificate of incorporation to effect a reverse split of the Company’s common stock at a ratio between 1:10 to 1:20 in order to satisfy requirements for the listing of the Company’s common stock on the NASDAQ Capital Market. In addition, the proposal approved by the stockholders provided that if the reverse split was effected, the number of shares of common stock that the Company is authorized to issue would be reduced from 150,000,000 to the greater of (A) 20,000,000 and (B) the number of shares equal to three (3) times the sum of the number of all shares of common stock outstanding and the number of shares of common stock issuable upon exercise or conversion of all outstanding options, warrants and convertible debt.
clrb Stockholders Equity Note Reverse Stock Split Conversion Ratio
StockholdersEquityNoteReverseStockSplitConversionRatio
1-for-20
CY2014Q2 clrb Common Stock Shares Previously Authorized
CommonStockSharesPreviouslyAuthorized
150000000 shares
CY2014Q1 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
275000 shares
clrb Amount Invoiced Under Clinical Trial Agreements
AmountInvoicedUnderClinicalTrialAgreements
334000 USD
us-gaap Related Party Transaction Amounts Of Transaction
RelatedPartyTransactionAmountsOfTransaction
62500 USD
CY2014Q2 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
254000 USD
CY2013Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
96278 shares
CY2014Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
1869000 USD
CY2013Q4 clrb Antidilution Option Reduced Rate
AntidilutionOptionReducedRate
19 shares

Files In Submission

Name View Source Status
0001144204-14-046802-index-headers.html Edgar Link pending
0001144204-14-046802-index.html Edgar Link pending
0001144204-14-046802.txt Edgar Link pending
0001144204-14-046802-xbrl.zip Edgar Link pending
clrb-20140630.xml Edgar Link completed
clrb-20140630.xsd Edgar Link pending
clrb-20140630_cal.xml Edgar Link unprocessable
clrb-20140630_def.xml Edgar Link unprocessable
clrb-20140630_lab.xml Edgar Link unprocessable
clrb-20140630_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
v385092_10q.htm Edgar Link pending
v385092_ex10-1.htm Edgar Link pending
v385092_ex10-2.htm Edgar Link pending
v385092_ex10-3.htm Edgar Link pending
v385092_ex31-1.htm Edgar Link pending
v385092_ex31-2.htm Edgar Link pending
v385092_ex32-1.htm Edgar Link pending